Arvinas (ARVN) CMO reports automatic RSU tax-withholding share sale

Rhea-AI Filing Summary

Arvinas, Inc. Chief Medical Officer Noah Berkowitz reported an automatic share disposition related to tax withholding. On March 18, he sold 6,435 shares of common stock at an average price of $11.1004 per share. According to the footnote, this sale was made automatically by the company to cover tax withholding obligations tied to the vesting and settlement of 25% of his restricted stock units granted on March 18, 2024, and did not represent a discretionary trade. After this transaction, he directly held 202,503 shares of Arvinas common stock.

Insights

Equity compensation and insider trading analyst

Non-discretionary tax sale of vested RSUs; routine, low-signal event.

The transaction shows Arvinas Chief Medical Officer Noah Berkowitz disposing of 6,435 common shares at $11.1004 per share. A footnote clarifies the sale was executed automatically by the company to satisfy tax withholding on vesting RSUs.

Such tax-cover sales are mechanical outcomes of equity compensation and do not reflect an active decision to reduce exposure or time the market. Following the sale, Berkowitz still holds 202,503 shares directly, indicating he retains a substantial equity stake in ARVN.

Because the sale was non-discretionary and relatively small compared with the remaining position, it is best viewed as routine compensation administration rather than a directional signal about Arvinas’ prospects. Future filings may outline additional vesting or similar tax-related transactions as RSU awards continue to settle.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Berkowitz Noah

(Last) (First) (Middle)

C/O ARVINAS, INC.

5 SCIENCE PARK, 395 WINCHESTER AVE.

(Street)

NEW HAVEN CONNECTICUT 06511

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ARVINAS, INC. [ ARVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/18/2026		S		6,435(1)	D	$11.1004	202,503	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of 25% of the reporting person's restricted stock units (RSUs) granted on March 18, 2024. The sale does not represent a discretionary trade.

Remarks:

	/s/ Jared Freedberg, as attorney-in-fact for Noah Berkowitz	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Arvinas (ARVN) Chief Medical Officer Noah Berkowitz report in this Form 4?

He reported an automatic sale of 6,435 Arvinas common shares at $11.1004 per share. The sale was executed to cover tax withholding obligations arising from the vesting and settlement of previously granted restricted stock units.

Was Noah Berkowitz’s recent Arvinas (ARVN) stock sale a discretionary trade?

No. The footnote explains the sale was made automatically by Arvinas to cover tax withholding on vesting RSUs. It specifies that the transaction does not represent a discretionary trade or an active market-timing decision by Berkowitz.

How many Arvinas (ARVN) shares did Noah Berkowitz sell and at what price?

He sold 6,435 shares of Arvinas common stock. The reported average sale price was $11.1004 per share, reflecting an automatic transaction executed to satisfy tax withholding obligations linked to vesting restricted stock units.

How many Arvinas (ARVN) shares does Noah Berkowitz hold after this Form 4 transaction?

After the tax-related sale, Noah Berkowitz directly holds 202,503 shares of Arvinas common stock. This remaining position indicates he continues to maintain a sizable equity stake in the company despite the automatic disposition of shares.

What triggered the tax-withholding sale reported by Arvinas (ARVN) CMO Noah Berkowitz?

The sale was triggered by the vesting and settlement of 25% of Berkowitz’s RSUs granted on March 18, 2024. To cover associated tax withholding obligations, Arvinas automatically sold 6,435 shares, as described in the Form 4 footnote.

Does the Arvinas (ARVN) Form 4 indicate any remaining derivative or option positions for Noah Berkowitz?

The derivative summary in the provided data is empty, showing no remaining derivative transactions in this filing. The reported holdings after the transaction consist of 202,503 shares of Arvinas common stock held directly, with no additional derivative positions listed.